AI assistant
Immunome Inc. — Director's Dealing 2020
Oct 2, 2020
32238_dirs_2020-10-01_3d3f57b6-b11a-4d27-bbf1-af040804f921.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01
Reporting Person: RAPP MICHAEL (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 827640 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (555554) | Direct | ||
| Warrant (right to buy) | $9.00 | 2023-06-02 | Series A Convertible Preferred Stock (166666) | Direct |
Footnotes
F1: The shares are held by BCM Advisory Partners LLC (the "LLC"). The Reporting Person is a managing member of the LLC and has voting and investment power with respect to shares held by the LLC.
F2: Each share of Series A Preferred Convertible Stock is convertible at any time at the option of the holder, without payment of additional
consideration, into Common Stock, on a one-for-one basis, has no expiration date and will automatically convert into shares of Common Stock
upon the closing of the Issuer's initial public offering.
F3: Immediately exercisable.